William A Stokes1, Megan Eguchi2, Arya Amini3, Mohammad K Hararah4, Ding Ding1, Jessica D McDermott5, Cathy J Bradley2, Sana D Karam6. 1. Department of Radiation Oncology, University of Colorado Denver, USA. 2. Department of Health Systems, Management, and Policy, Colorado School of Public Health, USA. 3. Department of Radiation Oncology, City of Hope Cancer Center, USA. 4. Department of Otolaryngology, University of Colorado Denver, USA. 5. Division of Medical Oncology, University of Colorado Denver, USA. 6. Department of Radiation Oncology, University of Colorado Denver, USA. Electronic address: sana.karam@ucdenver.edu.
Abstract
OBJECTIVES: Recent preclinical research has renewed interest in the interplay between glucose dysregulation and cancer. Metformin holds promise as an adjunctive antineoplastic agent in head and neck cancer (HNC). We aimed to explore the impact of metformin in HNC patients from a population-based dataset. PATIENTS & METHODS: Patients diagnosed with HNC from 2008 to 2011 were identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked dataset and categorized into three groups: non-diabetics (nD), diabetics not taking metformin (DnM), and diabetics taking metformin (D + M). Overall survival (OS) and cancer-specific survival (CSS) were compared between groups using Kaplan-Meier and Cox regression controlling for sociodemographic, clinical, and treatment covariates. The incidence of toxicities associated with HNC therapy was compared among groups using χ2 analysis. RESULTS: Among 1646 patients, there were 1144 nD, 378 DnM, and 124 D + M. 2-year OS rates was 65.6% for nD, 57.7% for DnM, and 73.4% for D + M by Kaplan-Meier (p < 0.01), and corresponding rates of 2-year CSS were 73.7%, 66.1%, and 88.8% (p < 0.01), respectively. On Cox multivariable analysis, OS among the three groups did not significantly differ; however, CSS was significantly worse among both nD versus DnM as compared to D + M. Toxicity rates were not significantly increased among D + M. CONCLUSION: HNC patients with diabetes taking metformin experience improved CSS. Prospective investigation of the addition of metformin to standard-of-care HNC therapy is warranted.
OBJECTIVES: Recent preclinical research has renewed interest in the interplay between glucose dysregulation and cancer. Metformin holds promise as an adjunctive antineoplastic agent in head and neck cancer (HNC). We aimed to explore the impact of metformin in HNC patients from a population-based dataset. PATIENTS & METHODS:Patients diagnosed with HNC from 2008 to 2011 were identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked dataset and categorized into three groups: non-diabetics (nD), diabetics not taking metformin (DnM), and diabetics taking metformin (D + M). Overall survival (OS) and cancer-specific survival (CSS) were compared between groups using Kaplan-Meier and Cox regression controlling for sociodemographic, clinical, and treatment covariates. The incidence of toxicities associated with HNC therapy was compared among groups using χ2 analysis. RESULTS: Among 1646 patients, there were 1144 nD, 378 DnM, and 124 D + M. 2-year OS rates was 65.6% for nD, 57.7% for DnM, and 73.4% for D + M by Kaplan-Meier (p < 0.01), and corresponding rates of 2-year CSS were 73.7%, 66.1%, and 88.8% (p < 0.01), respectively. On Cox multivariable analysis, OS among the three groups did not significantly differ; however, CSS was significantly worse among both nD versus DnM as compared to D + M. Toxicity rates were not significantly increased among D + M. CONCLUSION: HNC patients with diabetes taking metformin experience improved CSS. Prospective investigation of the addition of metformin to standard-of-care HNC therapy is warranted.
Authors: M A Pierotti; F Berrino; M Gariboldi; C Melani; A Mogavero; T Negri; P Pasanisi; S Pilotti Journal: Oncogene Date: 2012-06-04 Impact factor: 9.867
Authors: Brandon Faubert; Gino Boily; Said Izreig; Takla Griss; Bozena Samborska; Zhifeng Dong; Fanny Dupuy; Christopher Chambers; Benjamin J Fuerth; Benoit Viollet; Orval A Mamer; Daina Avizonis; Ralph J DeBerardinis; Peter M Siegel; Russell G Jones Journal: Cell Metab Date: 2012-12-27 Impact factor: 27.287
Authors: G Zhou; R Myers; Y Li; Y Chen; X Shen; J Fenyk-Melody; M Wu; J Ventre; T Doebber; N Fujii; N Musi; M F Hirshman; L J Goodyear; D E Moller Journal: J Clin Invest Date: 2001-10 Impact factor: 14.808
Authors: Bethany B Barone; Hsin-Chieh Yeh; Claire F Snyder; Kimberly S Peairs; Kelly B Stein; Rachel L Derr; Antonio C Wolff; Frederick L Brancati Journal: JAMA Date: 2008-12-17 Impact factor: 56.272
Authors: David Margel; David R Urbach; Lorraine L Lipscombe; Chaim M Bell; Girish Kulkarni; Peter C Austin; Neil Fleshner Journal: J Clin Oncol Date: 2013-08-05 Impact factor: 44.544
Authors: Vlad C Sandulache; John S Hamblin; Heath D Skinner; Mark W Kubik; Jeffrey N Myers; Jose P Zevallos Journal: Head Neck Date: 2014-01-29 Impact factor: 3.147
Authors: Abhinav Gupta; William Stokes; Megan Eguchi; Mohammad Hararah; Arya Amini; Adam Mueller; Rustain Morgan; Cathy Bradley; David Raben; Jessica McDermott; Sana D Karam Journal: Oral Oncol Date: 2019-02-04 Impact factor: 5.337